NORCROSS, Ga. , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH cirrhosis have been published in the
Interim analysis after 12-18 months of treatment to reaffirm phase 2 results, select optimal dosage and sizing and seamlessly roll into Phase 3 stage of NASH-RX Study Dr. Harold Shlevin , CEO, Discusses Plan at Annual Meeting of Stockholders NORCROSS, Ga. , Dec.
NORCROSS, Ga. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Harold H. Shlevin , Ph.D., president and chief executive officer, will present a corporate update via live webcast
NORCROSS, Ga. , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer , Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics , will be
Provides Update on NASH-RX Trial Plan NORCROSS, Ga. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended
NORCROSS, Ga. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers , a global leader in medical technology, in nonalcoholic
Baseline enhanced liver fibrosis (ELF) score taken at the beginning of NASH-CX trial accurately predicted which patients were at higher risk of liver-related outcomes NORCROSS, Ga. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics
NORCROSS, Ga. , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, and Providence Cancer Institute announced today they have received notice of issuance of U.S.
NORCROSS, Ga. , Aug. 09, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2019 .
NORCROSS, Ga. , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced it has submitted for assessment the Phase 3 protocol for using belapectin (GR-MD-02) for the treatment of compensated
